Circle Pharma and Verismo feature in coveted sessions.
ApexOnco Front Page
Recent articles
KITE-753 is to enter pivotal development – head-to-head against Yescarta.
The biggest Q3 agreement was AbbVie’s $700m swoop for Glenmark's trispecific T-cell engager.
And Treeline and HengRui also get in on the pan-RAS act.
A phase 3 trial of Hernexeos in adjuvant HER2m NSCLC is planned.
The group’s $8bn acquisition of Merus was the standout in the third quarter.
Datroway succeeds on PFS and OS in Tropion-Breast02, and an ESMO showdown beckons.
Key FDA decisions are expected to face delays.
